Introduction：Basic information about CAS 475085-57-5|MRE-269, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | MRE-269 |
|---|
| CAS Number | 475085-57-5 | Molecular Weight | 419.516 |
|---|
| Density | 1.2±0.1 g/cm3 | Boiling Point | 602.1±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C25H29N3O3 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 318.0±31.5 °C |
|---|
Names
| Name | {4-[(5,6-Diphenyl-2-pyrazinyl)(isopropyl)amino]butoxy}acetic acid |
|---|
| Synonym | More Synonyms |
|---|
MRE-269 BiologicalActivity
| Description | MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. |
|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Prostaglandin ReceptorResearch Areas >>Cardiovascular Disease |
|---|
| Target | IP Receptor |
|---|
| In Vitro | MRE-269 induces endothelium-independent vasodilation of rat extralobar pulmonary artery (EPA). MRE-269 or other IP receptor agonists including epoprostenol, iloprost, treprostinil and beraprost increase cAMP levels in hPASMC[1]. MRE-269 induces concentration-dependent vasodilation in LPA(+), LPA(-), and SPA(-)[3]. |
|---|
| In Vivo | The vasorelaxant effects of MRE-269 on rat small intralobar pulmonary artery (SIPA) and EPA are the same, while the other IP receptor agonists induce less vasodilation in SIPA than in EPA[1]. MRE-269 produces substantial relaxation of rat small pulmonary artery, although its effects are only significant at high concentrations of above 10 μM (pEC50, 4.98±0.22). By contrast, in rat small pulmonary veins, MRE-269 only produces minimal relaxation over the whole concentration range, with only significant relaxation occurring at the two highest doses of MRE-269 of 10 and 100 μM[2]. |
|---|
| References | [1]. Fuchikami C, et al. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcin [2]. Orie NN, et al. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins. Prostaglandins Other Lipid Mediat. 2013 Oct;106:1-7 [3]. Kuwano K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses |
|---|
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|
| Boiling Point | 602.1±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C25H29N3O3 |
|---|
| Molecular Weight | 419.516 |
|---|
| Flash Point | 318.0±31.5 °C |
|---|
| Exact Mass | 419.220886 |
|---|
| PSA | 75.55000 |
|---|
| LogP | 5.09 |
|---|
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
|---|
| Index of Refraction | 1.588 |
|---|
| InChIKey | OJQMKCBWYCWFPU-UHFFFAOYSA-N |
|---|
| SMILES | CC(C)N(CCCCOCC(=O)O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1 |
|---|
| Storage condition | 2-8℃ |
|---|
Synonyms
| Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]- |
| MRE-269 |
| 2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID |
| 2-(4-{[(3,5-dichlorophenyl)carbamoyl]amino}phenoxy)-2-methylpropanoic acid |
| {4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetic acid |
| {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid |
| 4-(3,5-dichlorophenylureido)phenoxyisobutyric acid |
| {4-[(5,6-Diphenyl-2-pyrazinyl)(isopropyl)amino]butoxy}acetic acid |
| ACT-333679 |
| 2-<4<<<(3,5-dichlorophenyl)amino>carbonyl>amino>phenoxy>-2-methylpropionic acid |
| 2-{4-[N'-(3,5-dichlorophenyl)ureido]phenoxy}isobutyric acid |
| 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid |
| Propanoic acid,2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl |
